SRR612623
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.347
- OXIDATIVE_PHOSPHORYLATION+0.308
- FATTY_ACID_METABOLISM+0.289
- PANCREAS_BETA_CELLS+0.274
- BILE_ACID_METABOLISM+0.239
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.232
- APICAL_JUNCTION+0.216
- KRAS_SIGNALING_DN+0.210
- INTERFERON_ALPHA_RESPONSE+0.195
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.189
Top 10 suppressed
- MYC_TARGETS_V2-0.577
- G2M_CHECKPOINT-0.495
- E2F_TARGETS-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.437
- MYC_TARGETS_V1-0.375
- TNFA_SIGNALING_VIA_NFKB-0.370
- DNA_REPAIR-0.325
- CHOLESTEROL_HOMEOSTASIS-0.241
- NOTCH_SIGNALING-0.237
- MTORC1_SIGNALING-0.234
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1399092 | GTEX | — | 0.881 |
| 2 | SRR655435 | GTEX | — | 0.860 |
| 3 | SRR1430570 | GTEX | — | 0.856 |
| 4 | ERR2598267 | fetal | fetal | 0.848 |
| 5 | SRR1328919 | GTEX | — | 0.839 |
| 6 | BS_PKW05VZV | high-grade glioma | — | 0.837 |
| 7 | ERR2598329 | fetal | fetal | 0.837 |
| 8 | SRR1387178 | GTEX | — | 0.830 |
| 9 | SRR600754 | GTEX | — | 0.827 |
| 10 | BS_ET8CJXSF | pilocytic astrocytoma | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.347 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.308 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.289 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.274 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.239 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.232 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.216 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.195 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.189 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.183 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.178 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.176 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.164 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.142 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.141 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.133 | Inavolisib | — uncovered |
| COMPLEMENT | 0.127 | Inavolisib | — uncovered |
| COAGULATION | 0.125 | Binimetinib | — uncovered |